Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma

Authors: Jarinya Khoontawad, Nuttanan Hongsrichan, Yaovalux Chamgramol, Porntip Pinlaor, Chaisiri Wongkham, Puangrat Yongvanit, Chawalit Pairojkul, Narong Khuntikeo, Sittiruk Roytrakul, Thidarut Boonmars, Somchai Pinlaor

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

A proteomic-based approach was used to search for potential markers in the plasma of hamsters in which cholangiocarcinoma (CCA) was induced by Opisthorchis viverrini infection and N-nitrosodimethylamine treatment. The plasma proteins of CCA-induced hamsters were resolved by 1-D PAGE, digested by trypsin, and analyzed by LC-MS/MS. From the criteria of protein ID scores >15 and an overexpression of at least three times across all time points, 37 proteins were selected. These overexpressed proteins largely consisted of signal transduction, structural, transport, and transcriptional proteins in the order. Among the most frequently upregulated proteins, exostosin 1 (EXT1) was selected for further validation. By western blot analysis, the EXT1 expression level in the plasma of hamster CCA was significantly higher than that of controls at 1 month and thereafter. Immunohistochemistry revealed that EXT1 was expressed at vascular walls and fibroblasts at 21 days (before tumor onset) and at 2 months (early CCA) posttreatment. Its expression was also observed in bile duct cancer cells during tumor progression at 6 months posttreatment. In the human CCA tissue microarray, EXT1 immunoreactivity was found not only in vascular walls and fibroblasts but also in bile duct cancer cells and was positive in 89.7 % (61/68) of the cases. By ELISA and immunoblotting, plasma EXT1 level was significantly higher in human CCA compared to healthy controls. In conclusion, these results suggest that increased expression of EXT1 level in the plasma might be involved in CCA genesis and might be a potential biomarker of CCA.
Literature
1.
go back to reference Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579–85.PubMedCrossRef Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579–85.PubMedCrossRef
2.
go back to reference Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef
3.
go back to reference Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, northeast thailand. Trop Med Int Health. 2004;9:588–94.PubMedCrossRef Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, northeast thailand. Trop Med Int Health. 2004;9:588–94.PubMedCrossRef
4.
go back to reference Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from thailand. Curr Opin Gastroenterol. 2008;24:349–56.PubMedCrossRef Sripa B, Pairojkul C. Cholangiocarcinoma: lessons from thailand. Curr Opin Gastroenterol. 2008;24:349–56.PubMedCrossRef
6.
go back to reference Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol. 2009;25:279–84.PubMedCrossRef
7.
go back to reference Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected syrian golden hamsters. Cancer Res. 1978;38:4634–9.PubMed Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected syrian golden hamsters. Cancer Res. 1978;38:4634–9.PubMed
8.
go back to reference Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, Pinlaor P, et al. Involvement of mmp-9 in peribiliary fibrosis and cholangiocarcinogenesis via rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010;127:2576–87.PubMedCrossRef Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, Pinlaor P, et al. Involvement of mmp-9 in peribiliary fibrosis and cholangiocarcinogenesis via rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010;127:2576–87.PubMedCrossRef
9.
go back to reference Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.PubMedCentralPubMedCrossRef Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.PubMedCentralPubMedCrossRef
10.
go back to reference Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics. 2004;4:2766–75.PubMedCrossRef Juan HF, Chen JH, Hsu WT, Huang SC, Chen ST, Yi-Chung Lin J, et al. Identification of tumor-associated plasma biomarkers using proteomic techniques: from mouse to human. Proteomics. 2004;4:2766–75.PubMedCrossRef
11.
go back to reference Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.PubMedCrossRef Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–67.PubMedCrossRef
12.
go back to reference Khoontawad J, Laothong U, Roytrakul S, Pinlaor P, Mulvenna J, Wongkham C, et al. Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection. PLoS One. 2012;7:e45460.PubMedCentralPubMedCrossRef Khoontawad J, Laothong U, Roytrakul S, Pinlaor P, Mulvenna J, Wongkham C, et al. Proteomic identification of plasma protein tyrosine phosphatase alpha and fibronectin associated with liver fluke, Opisthorchis viverrini, infection. PLoS One. 2012;7:e45460.PubMedCentralPubMedCrossRef
13.
go back to reference Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.PubMedCrossRef Guo J, Wang W, Liao P, Lou W, Ji Y, Zhang C, et al. Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci. 2009;100:2292–301.PubMedCrossRef
14.
go back to reference Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin a2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010;40:1203–12.PubMedCentralPubMedCrossRef Yonglitthipagon P, Pairojkul C, Chamgramol Y, Mulvenna J, Sripa B. Up-regulation of annexin a2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. Int J Parasitol. 2010;40:1203–12.PubMedCentralPubMedCrossRef
15.
go back to reference Lin X, Gan L, Klein WH, Wells D. Expression and functional analysis of mouse ext1, a homolog of the human multiple exostoses type 1 gene. Biochem Biophys Res Commun. 1998;248:738–43.PubMedCrossRef Lin X, Gan L, Klein WH, Wells D. Expression and functional analysis of mouse ext1, a homolog of the human multiple exostoses type 1 gene. Biochem Biophys Res Commun. 1998;248:738–43.PubMedCrossRef
16.
go back to reference Lin X, Wells D. Isolation of the mouse cdna homologous to the human ext1 gene responsible for hereditary multiple exostoses. DNA Seq. 1997;7:199–202.PubMed Lin X, Wells D. Isolation of the mouse cdna homologous to the human ext1 gene responsible for hereditary multiple exostoses. DNA Seq. 1997;7:199–202.PubMed
17.
go back to reference de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol. 2012;226:219–28.PubMedCrossRef de Andrea CE, Hogendoorn PC. Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol. 2012;226:219–28.PubMedCrossRef
18.
go back to reference Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, et al. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71–9.PubMedCentralPubMed Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, et al. Genetic heterogeneity in families with hereditary multiple exostoses. Am J Hum Genet. 1993;53:71–9.PubMedCentralPubMed
19.
go back to reference Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB, et al. Diminished levels of the putative tumor suppressor proteins ext1 and ext2 in exostosis chondrocytes. Cell Motil Cytoskeleton. 2001;48:149–62.PubMedCrossRef Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB, et al. Diminished levels of the putative tumor suppressor proteins ext1 and ext2 in exostosis chondrocytes. Cell Motil Cytoskeleton. 2001;48:149–62.PubMedCrossRef
20.
go back to reference Osterholm C, Barczyk MM, Busse M, Gronning M, Reed RK, Kusche-Gullberg M. Mutation in the heparan sulfate biosynthesis enzyme ext1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem. 2009;284:34935–43.PubMedCrossRef Osterholm C, Barczyk MM, Busse M, Gronning M, Reed RK, Kusche-Gullberg M. Mutation in the heparan sulfate biosynthesis enzyme ext1 influences growth factor signaling and fibroblast interactions with the extracellular matrix. J Biol Chem. 2009;284:34935–43.PubMedCrossRef
21.
go back to reference Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 2002;1573:346–55.PubMedCrossRef Zak BM, Crawford BE, Esko JD. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim Biophys Acta. 2002;1573:346–55.PubMedCrossRef
23.
go back to reference Schmale GA, Conrad 3rd EU, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76:986–92.PubMed Schmale GA, Conrad 3rd EU, Raskind WH. The natural history of hereditary multiple exostoses. J Bone Joint Surg Am. 1994;76:986–92.PubMed
24.
go back to reference Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of ntpdase2. J Biol Chem. 2005;280:22986–92.PubMedCrossRef Jhandier MN, Kruglov EA, Lavoie EG, Sevigny J, Dranoff JA. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of ntpdase2. J Biol Chem. 2005;280:22986–92.PubMedCrossRef
25.
go back to reference Juttijudata P, Chiemchaisri C, Palavatana C, Churnratanakul S. Causes of cholestasis in Thailand. A study of 276 consecutive patients. Am J Surg. 1984;147:360–6.PubMedCrossRef Juttijudata P, Chiemchaisri C, Palavatana C, Churnratanakul S. Causes of cholestasis in Thailand. A study of 276 consecutive patients. Am J Surg. 1984;147:360–6.PubMedCrossRef
26.
go back to reference Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66:6622–7.PubMedCrossRef Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res. 2006;66:6622–7.PubMedCrossRef
27.
go back to reference Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.PubMedCrossRef Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet. 2012;44:690–3.PubMedCrossRef
28.
go back to reference Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:44–54.CrossRef Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2012;9:44–54.CrossRef
29.
go back to reference McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, et al. The putative tumour suppressor ext1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19:158–61.PubMedCrossRef McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP, et al. The putative tumour suppressor ext1 alters the expression of cell-surface heparan sulfate. Nat Genet. 1998;19:158–61.PubMedCrossRef
30.
go back to reference Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors ext1 and ext2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265–8.PubMedCrossRef Lind T, Tufaro F, McCormick C, Lindahl U, Lidholt K. The putative tumor suppressors ext1 and ext2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem. 1998;273:26265–8.PubMedCrossRef
31.
go back to reference Tatrai P, Egedi K, Somoracz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem. 2010;58:429–41.PubMedCrossRef Tatrai P, Egedi K, Somoracz A, van Kuppevelt TH, Ten Dam G, Lyon M, et al. Quantitative and qualitative alterations of heparan sulfate in fibrogenic liver diseases and hepatocellular cancer. J Histochem Cytochem. 2010;58:429–41.PubMedCrossRef
32.
go back to reference Koo CY, Sen YP, Bay BH, Yip GW. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008;3:151–8.PubMedCrossRef Koo CY, Sen YP, Bay BH, Yip GW. Targeting heparan sulfate proteoglycans in breast cancer treatment. Recent Pat Anticancer Drug Discov. 2008;3:151–8.PubMedCrossRef
33.
go back to reference Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5178–86.CrossRef Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 2004;10:5178–86.CrossRef
35.
go back to reference Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27:549–50.PubMedCrossRef Gabbiani G, Ryan GB, Majne G. Presence of modified fibroblasts in granulation tissue and their possible role in wound contraction. Experientia. 1971;27:549–50.PubMedCrossRef
Metadata
Title
Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma
Authors
Jarinya Khoontawad
Nuttanan Hongsrichan
Yaovalux Chamgramol
Porntip Pinlaor
Chaisiri Wongkham
Puangrat Yongvanit
Chawalit Pairojkul
Narong Khuntikeo
Sittiruk Roytrakul
Thidarut Boonmars
Somchai Pinlaor
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1137-9

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine